PYPD: Polypid is Enhancing Surgical Outcomes

NASDAQ:PYPD

VIEW THE FULL PYPD PROFILE

PolyPid (NASDAQ:PYPD) is a global late clinical-stage biopharma company that specializes in developing, producing, and selling innovative therapies to enhance surgical results. The company’s PLEX (Polymer-Lipid Encapsulation matriX) technology is a distinct system that is applied at the surgical site to offer controlled and continuous medication release. PYPD’s products administer medications directly to a surgical site over varying durations, ranging from days to months. This approach helps in addressing localized medical issues like infection, pain, inflammation, and cancer, thereby enhancing patient outcomes.

The company’s primary focus is on treating Surgical Site Infections (SSIs), which are among the most common Healthcare Acquired Infections (HAIs) and have significant adverse effects on patient health and healthcare systems. PolyPid aims to decrease overall surgical infection rates, particularly those caused by antibiotic-resistant bacteria, which are identified by the FDA as a critical global public health concern. The company’s strategy involves advancing PYPD’s proprietary product pipeline and partnering with pharmaceutical companies to enhance the local delivery of Polypid’s medications.

D-PLEX₁₀₀

PolyPid’s lead product candidate, D-PLEX₁₀₀, is engineered to deliver prolonged and controlled antibacterial activity directly at the surgical site, aiming to prevent surgical site infections (SSIs). Upon administration into the surgical site, D-PLEX₁₀₀ utilizes the PLEX (Polymer-Lipid Encapsulation matriX) technology in conjunction with Active Pharmaceutical Ingredients. This combination facilitates a sustained release of the broad-spectrum antibiotic doxycycline, ensuring a heightened local concentration of the drug for up to 30 days, thereby mitigating SSIs. Additionally, there is potential for D-PLEX₁₀₀ to fight SSIs caused by antibiotic-resistant bacteria at the surgical site. Recognizing its potential, D-PLEX₁₀₀ has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for SSIs prevention in patients undergoing elective colorectal surgery. Currently, D-PLEX₁₀₀ is being evaluated in the Phase 3 SHIELD II trial, focusing on preventing surgical site infections in patients undergoing open abdominal colorectal surgery with large incisions.

SHIELD II

SHIELD II (Surgical Site Hospital-acquired Infection Prevention with Local D-PLEX) is a multinational Phase 3 trial designed to investigate the efficacy of D-PLEX₁₀₀ in conjunction with standard care, including prophylactic systemic antibiotics, compared to standard care alone, in preventing post-abdominal-surgery incisional infections among patients undergoing abdominal colorectal surgeries with large incisions. The trial’s primary endpoint will be determined by assessing the proportion of subjects experiencing surgical site infections (SSI), as evaluated by an independent adjudication committee, as well as the occurrence of reintervention or mortality for any reason within 30 days post-surgery. Patient safety will be closely monitored for an additional 30 days. Enrollment for the trial will span centers in the United States, Europe, and Israel.

Significant progress has been made in the ongoing SHIELD II Phase 3 trial, which has enrolled over 100 patients undergoing colorectal abdominal surgery. Currently, around 40 centers are involved, and the company plans to conduct an interim analysis once about 400 patients have completed their 30-day follow-up, expected by mid-2024. Top-line results from the trial are anticipated in the latter half of 2024. This trial’s comprehensive assessment aims to provide valuable insights into the potential benefits of D-PLEX₁₀₀ in preventing surgical site infections, contributing to advancements in patient care and surgical outcomes.

Q4 2023 Financial Updates

In February 2024, PolyPid announced financial results for the fourth quarter and full year of 2023. In Q4 2023, research and development (R&D) expenditures, primarily attributable to the ongoing SHIELD II Phase 3 trial, remained stable year-over-year, with a marginal decrease to $4.6 million from $4.7 million in the same period of 2022. General and administrative (G&A) costs declined to $1.2 million compared to $1.6 million in the corresponding period of the previous year, while expenses for marketing and business development also decreased to $0.2 million from $0.4 million. The company registered a net loss of $6.4 million for the quarter, or ($3.97) per diluted share, compared to a net loss of $6.6 million, or ($9.90) per diluted share, in the corresponding period of 2022.

For the full year of 2023, R&D expenses decreased to $16.1 million from $28 million in 2022, primarily due to the completion of the SHIELD I Phase 3 clinical trial. G&A outlays for the year amounted to $5.5 million, down from $8.0 million in 2022, and expenses related to marketing and business development decreased to $1.2 million from $2.9 million in the previous year. These reductions were attributable to the company’s cost-reduction plan announced in October 2022 and further cost-saving initiatives during 2023. The net loss for the year stood at $23.9 million, or ($16.93) per diluted share, compared to a net loss of $39.6 million, or ($61.09) per diluted share, in 2022. As of December 31, 2023, the company held cash and cash equivalents amounting to $5.3 million. In January 2024, PolyPid successfully secured $16 million in gross proceeds through a private placement financing (PIPE), extending its cash runway through late third quarter 2024.

Conclusion

In summary, PolyPid (NASDAQ:PYPD) is a global biopharmaceutical company specializing in innovative therapies aimed at optimizing surgical outcomes. The company’s PLEX technology targets localized medical issues such as infection and inflammation, with a specific focus on reducing Surgical Site Infections (SSIs). Management remains focused on continued progress in the SHIELD II trial, with enrollment surpassing 100 patients, with anticipated top-line results expected in late 2024. Furthermore, recent financial updates demonstrate a commitment to fiscal responsibility and sustainability, positioning PolyPid for future growth and innovation within the biopharmaceutical sector.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Go Source